Receptor News and Research

RSS

Quantum rods light up pancreatic cancer cells

Quantum dots have shown promise as ultrabright contrast agents for use in a variety of cancer imaging studies. Now, a team of investigators at the Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer Platform Partnership, headed by Paras Prasad, Ph.D., of the State University of New York at Buffalo, has shown that quantum rods may perform even better than their spherical cousins.

18 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

Austrian scientists identify common mechanism underlying acute respiratory disease syndrome

The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). This fatal condition is a massive reaction of the body during which the lung becomes severely damaged. ARDS can be induced by various bacterial and viral infections, but also by chemical agents.

17 Apr 2008

New molecule could be key to anti-heart attack drug

When too many blood platelets stick together in the bloodstream, they form dangerous clots that can clog blood vessels and cause a heart attack. If a clot doesn't get dissolved or rapidly removed, it can cause permanent damage or even death.

17 Apr 2008

No link between aromatase inhibitors and cardiovascular problems

New evidence has emerged that, contrary to some current fears, aromatase inhibitors (AIs) are not associated with an increased risk of heart problems in women who take them to prevent their breast cancer recurring.

17 Apr 2008

New drug for melanoma riluzole shows promise

Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

16 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Exposure to organic solvents linked to disturbances in brain circuitry

Chronic occupational exposure to organic solvents, found in materials such as paints, printing and dry cleaning agents, is widespread all over the world, and is thought to damage the central nervous system.

16 Apr 2008

Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients

For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.

15 Apr 2008

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

Blood pressure drugs halt pancreatic cancer cell growth

Researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia are inching closer to understanding how common blood pressure medications might help prevent the spread of pancreatic cancer.

15 Apr 2008

Targeted therapy combo overcomes treatment resistance in liver cancer

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

13 Apr 2008

Targeted therapies overcome treatment resistance in liver cancer cell lines

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

13 Apr 2008

Discovery of link between protein, prognosis in breast cancer

Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis.

13 Apr 2008

What we eat and drink affects our risk of cancer

A healthy diet and lifestyle protect against a wide range of diseases, and new research presented at the American Association for Cancer Research 2008 Annual Meeting, April 12-16, shows that cancer is no exception.

13 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Triple-negative breast cancers doesn't always mean cancer spread

Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.

13 Apr 2008

Scientists uncover the potential to control adult stem cells

Research presented at the UK National Stem Cell Network Annual Science Meeting in Edinburgh represents a step towards the use of Adult Stem Cells (ASCs) to repair damaged tissue.

11 Apr 2008

Better understanding of how T-cell leukemias and other disorders arise

Contrary to the currently accepted model of T-cell development, researchers at the University of Pennsylvania School of Medicine have found that juvenile cells on their way to becoming mature immune cells can develop into either T cells or other blood-cell types versus only being committed to the T-cell path.

10 Apr 2008

Double binding sites on tumor target may provide future combination therapy

Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.

9 Apr 2008